KPTI News and Press, Karyopharm Therapeutics Inc. From 08/22/19

Karyopharm Therapeutics (NASDAQ: KPTI ) slips  1%  premarket on heels of  Phase 2b data on XPOVIO (selinexor), combined with low-dose dexamethasone, in patients with heavily pretreated triple class refractory multiple myeloma (MM). The results were just published in the onlin...

-- XPOVIO was Recently Approved by the FDA for the Treatment of Patients with Multiple Myeloma whose Disease is Refractory to Proteasome Inhibitors, Immunomodulatory Agents, and an Anti-CD38 Monoclonal Antibody -- -- In STORM, XPOVIO Achieved a 26% Overall Response Rate...

NEW YORK, NY / ACCESSWIRE / August 13, 2019 / Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Karyopharm Therapeutics Inc. (“Karyopharm” or the “Company”) (NASDAQ:KPTI) of the September 23, 2019 deadline to seek the role ...

Karyopharm Therapeutics Inc. (KPTI) Q2 2019 Earnings Conference Call August 6, 2019 8:30 A.M. ET Company Participants Ian Karp - Vice President, Investor and Public Relations Dr. Michael Kauffman - Chief Executive Officer Perry Monaco - Senior Vice President, Sales Mike Mason -...

Karyopharm (NASDAQ: KPTI ) Q2 results : License and other revenue: $9.5M (-52%). Net loss: ($43.4M), loss/share: ($0.71). More news on: Karyopharm Therapeutics Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ...

SAN FRANCISCO, CA / ACCESSWIRE / July 30, 2019 / Hagens Berman Sobol Shapiro LLP alerts investors in Karyopharm Therapeutics Inc.’s (NASDAQ: KPTI) April 28, 2017 and May 7, 2018 public offerings to the firm’s ongoing investigation into possible securities law violation...

NEWTON, Mass., July 30, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, announced today that it will report second quarter 2019 financial results on Tuesday, August 6, 2019. Karyopharm's management team will host a conference ...

Shareholder rights law firm Robbins Arroyo LLP announces that a purchaser of Karyopharm Therapeutics Inc. (NASDAQ: KPTI) filed a class action complaint for alleged violations of the Securities Exchange Act of 1934 between March 2, 2017 and February 22, 2019, and the Securities Exchange Act ...

Lately, Karyopharm Therapeutics ( KPTI ) has been one of the top trending tickers in the healthcare industry. The stock is up by 55.65% since July 1. Ironically, the stock is down by 5.98% in 2019 YTD. Still, this has not reduced the overall interest in the stock, from investors as well as ana...

Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of Karyopharm Therapeutics, Inc. (“Karyopharm” or the “Company”) (NASDAQ: KPTI ) investors concerning the Company and its officers’ possible violations of federal sec...